Amarin | AMRN - Ebit

Stock Price
15.42
Daily Change
0.08 0.52%
Monthly
-1.41%
Yearly
86.32%
Q1 Forecast
14.88

Amarin reported $-1.7M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
AbbVie USD 5.81B 4.36B Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amarin USD -1.7M 8.47M Sep/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
DBV Technologies USD -34.28M 6.83M Sep/2025
Esperion Therapeutics USD -16.03M 11.51M Sep/2024
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Heron Therapeutics USD -4.46M 5.76M Sep/2024
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
Nektar Therapeutics USD -34.34M 3.68M Sep/2024
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Novartis USD -9.19B 13.87B Jun/2025